You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

LIPTRUZET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Liptruzet, and what generic alternatives are available?

Liptruzet is a drug marketed by Organon and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LIPTRUZET?
  • What are the global sales for LIPTRUZET?
  • What is Average Wholesale Price for LIPTRUZET?
Summary for LIPTRUZET
Drug patent expirations by year for LIPTRUZET

US Patents and Regulatory Information for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 ⤷  Sign Up ⤷  Sign Up
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LIPTRUZET

See the table below for patents covering LIPTRUZET around the world.

Country Patent Number Title Estimated Expiration
Bulgaria 63630 ⤷  Sign Up
China 1087288 ⤷  Sign Up
Argentina 003459 FORMA III CRISTALINA DE ATORVASTATINA Y SUS HIDRATOS Y COMPOSICIONES FARMACEUTICAS CON LA MISMA. ⤷  Sign Up
European Patent Office 0848705 FORMES CRISTALLINES D'HEMI-SEL DE CALCIUM D'ACIDE R-(R*,R*) -2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- (PHENYLAMINO)CARBONYL -1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE) (CRYSTALLINE R-(R*,R*) -2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- (PHENYLAMINO)CARBONYL -1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN)) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LIPTRUZET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 92545 Luxembourg ⤷  Sign Up PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599 92544 Luxembourg ⤷  Sign Up PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
0720599 CR 2014 00048 Denmark ⤷  Sign Up PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
0720599 CR 2014 00050 Denmark ⤷  Sign Up PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.